Novadaq Technologies Inc.  

(Public, NASDAQ:NVDQ)   Watch this stock  
Find more results for NVDQ
-0.20 (-1.65%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.75 - 12.27
52 week 9.40 - 18.24
Open 12.15
Vol / Avg. 0.00/233,943.00
Mkt cap 681.26M
P/E     -
Div/yield     -
EPS -0.35
Shares 55.57M
Beta 0.67
Inst. own     -
Jul 28, 2015
Q2 2015 Novadaq Technologies Inc Earnings Call
Jul 28, 2015
Q2 2015 Novadaq Technologies Inc Earnings Release
Jun 10, 2015
Novadaq Technologies Inc at William Blair Annual Growth Stock Conference
May 27, 2015
Novadaq Technologies Inc at Craig-Hallum Capital Group Institutional Investor Conference
May 21, 2015
Novadaq Technologies Inc Annual Shareholders Meeting (Estimated)
May 19, 2015
Novadaq Technologies Inc at UBS Global Healthcare Conference
May 14, 2015
Novadaq Technologies Inc at Bank of America Merrill Lynch Health Care Conference
May 13, 2015
Novadaq Technologies Inc Annual Shareholders Meeting
May 4, 2015
Novadaq Technologies Inc at Bloom Burton & Co Healthcare Investor Conference
More events from DailyFinance »    


5090 Explorer Dr Suite 202
+1-905-6293822 (Phone)
+1-905-6290282 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novadaq Technologies Inc. develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company generates revenues from the sale of medical devices and consumables, capital devices or consumable products, the rental of capital devices, royalties, upfront payments received from partners for exclusive sales and marketing rights, and extended warranty services agreements in connection with capital sales. The Company’s SPY imaging products are SPY Elite, FIREFLY, LUNA, PINPOINT, CO2 HEART LASER systems and DermACELL Advanced Decellularized Dermis. The SPY Imaging System is United States Food and Drug Administration (FDA) cleared for use in seven surgical specialties, including coronary artery bypass, cardiovascular, plastic, reconstructive, micro, organ transplant and gastrointestinal surgery.

Officers and directors

Arun Menawat President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Roger Deck Chief Financial Officer
Bio & Compensation  - Reuters
Anthony F. Griffiths Independent Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Patrice E. Merrin Director
Age: 66
Bio & Compensation  - Reuters
Robert S. White Director
Bio & Compensation  - Reuters
Aaron Davidson Independent Director
Age: 46
Bio & Compensation  - Reuters
Harold O. Koch Jr. Independent Director
Age: 59
Bio & Compensation  - Reuters